The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value.

Janssens, Esther; Flamaing, Johan; Vandermeulen, Corinne; Peetermans, Willy E; Desmet, Stefanie; De Munter, Paul

Janssens, Esther; Flamaing, Johan; Vandermeulen, Corinne; Peetermans, Willy E; Desmet, Stefanie; De Munter, Paul.

Afiliação

Janssens E; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Flamaing J; Department of Geriatric Medicine, University Hospitals Leuven, Leuven, Belgium.
Vandermeulen C; Department of Public Health & Primary Care, KU Leuven, Leuven, Belgium.
Peetermans WE; Department of Public Health & Primary Care, KU Leuven, Leuven, Belgium.
Desmet S; Leuven University Vaccinology Centre, Leuven, Belgium.
De Munter P; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.

Acta Clin Belg ; 78(1): 78-86, 2023 Feb.

Article em En | MEDLINE | ID: mdl-35171752

Assuntos

Infecções Pneumocócicas; Streptococcus pneumoniae; Criança; Adulto; Humanos; Lactente; Vacina Pneumocócica Conjugada Heptavalente; Vacinas Conjugadas; Infecções Pneumocócicas/epidemiologia; Infecções Pneumocócicas/prevenção & controle; Vacinas Pneumocócicas

Palavras-chave

20-valent pneumococcal conjugate vaccine; Belgium; PCV20; epidemiology; serotype replacement; vaccine coverage

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções Pneumocócicas / Streptococcus pneumoniae Limite: Adult / Child / Humans / Infant Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google